224 related articles for article (PubMed ID: 22101743)
1. Dynamic contrast enhanced-MRI for the detection of pathological complete response to neoadjuvant chemotherapy for locally advanced rectal cancer.
Gollub MJ; Gultekin DH; Akin O; Do RK; Fuqua JL; Gonen M; Kuk D; Weiser M; Saltz L; Schrag D; Goodman K; Paty P; Guillem J; Nash GM; Temple L; Shia J; Schwartz LH
Eur Radiol; 2012 Apr; 22(4):821-31. PubMed ID: 22101743
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic parameters from 3-Tesla DCE-MRI as surrogate biomarkers of antitumor effects of bevacizumab plus FOLFIRI in colorectal cancer with liver metastasis.
Hirashima Y; Yamada Y; Tateishi U; Kato K; Miyake M; Horita Y; Akiyoshi K; Takashima A; Okita N; Takahari D; Nakajima T; Hamaguchi T; Shimada Y; Shirao K
Int J Cancer; 2012 May; 130(10):2359-65. PubMed ID: 21780098
[TBL] [Abstract][Full Text] [Related]
3. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) for pretreatment prediction of neoadjuvant chemotherapy response in locally advanced hypopharyngeal cancer.
Guo W; Zhang Y; Luo D; Yuan H
Br J Radiol; 2020 Nov; 93(1115):20200751. PubMed ID: 32915647
[No Abstract] [Full Text] [Related]
4. Dynamic contrast-enhanced MRI: Use in predicting pathological complete response to neoadjuvant chemoradiation in locally advanced rectal cancer.
Tong T; Sun Y; Gollub MJ; Peng W; Cai S; Zhang Z; Gu Y
J Magn Reson Imaging; 2015 Sep; 42(3):673-80. PubMed ID: 25652254
[TBL] [Abstract][Full Text] [Related]
5. Dynamic contrast-enhanced MRI in advanced nonsmall-cell lung cancer patients treated with first-line bevacizumab, gemcitabine, and cisplatin.
Chang YC; Yu CJ; Chen CM; Hu FC; Hsu HH; Tseng WY; Ting-Fang Shih T; Yang PC; Chih-Hsin Yang J
J Magn Reson Imaging; 2012 Aug; 36(2):387-96. PubMed ID: 22517425
[TBL] [Abstract][Full Text] [Related]
6. Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response.
Yopp AC; Schwartz LH; Kemeny N; Gultekin DH; Gönen M; Bamboat Z; Shia J; Haviland D; D'Angelica MI; Fong Y; DeMatteo RP; Allen PJ; Jarnagin WR
Ann Surg Oncol; 2011 Aug; 18(8):2192-9. PubMed ID: 21286939
[TBL] [Abstract][Full Text] [Related]
7. DCE-MRI biomarkers of tumour heterogeneity predict CRC liver metastasis shrinkage following bevacizumab and FOLFOX-6.
O'Connor JP; Rose CJ; Jackson A; Watson Y; Cheung S; Maders F; Whitcher BJ; Roberts C; Buonaccorsi GA; Thompson G; Clamp AR; Jayson GC; Parker GJ
Br J Cancer; 2011 Jun; 105(1):139-45. PubMed ID: 21673686
[TBL] [Abstract][Full Text] [Related]
8. Pathological response and safety of two neoadjuvant strategies with bevacizumab in MRI-defined locally advanced T3 resectable rectal cancer: a randomized, noncomparative phase II study.
Borg C; André T; Mantion G; Boudghène F; Mornex F; Maingon P; Adenis A; Azria D; Piutti M; Morsli O; Bosset JF
Ann Oncol; 2014 Nov; 25(11):2205-2210. PubMed ID: 25122693
[TBL] [Abstract][Full Text] [Related]
9. Pancreatic cancer: utility of dynamic contrast-enhanced MR imaging in assessment of antiangiogenic therapy.
Akisik MF; Sandrasegaran K; Bu G; Lin C; Hutchins GD; Chiorean EG
Radiology; 2010 Aug; 256(2):441-9. PubMed ID: 20515976
[TBL] [Abstract][Full Text] [Related]
10. Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer.
Ah-See ML; Makris A; Taylor NJ; Harrison M; Richman PI; Burcombe RJ; Stirling JJ; d'Arcy JA; Collins DJ; Pittam MR; Ravichandran D; Padhani AR
Clin Cancer Res; 2008 Oct; 14(20):6580-9. PubMed ID: 18927299
[TBL] [Abstract][Full Text] [Related]
11. DCE-MRI parameters have potential to predict response of locally advanced breast cancer patients to neoadjuvant chemotherapy and hyperthermia: a pilot study.
Craciunescu OI; Blackwell KL; Jones EL; Macfall JR; Yu D; Vujaskovic Z; Wong TZ; Liotcheva V; Rosen EL; Prosnitz LR; Samulski TV; Dewhirst MW
Int J Hyperthermia; 2009; 25(6):405-15. PubMed ID: 19657852
[TBL] [Abstract][Full Text] [Related]
12. Role of diffusion-weighted imaging as an adjunct to contrast-enhanced breast MRI in evaluating residual breast cancer following neoadjuvant chemotherapy.
Hahn SY; Ko EY; Han BK; Shin JH; Ko ES
Eur J Radiol; 2014 Feb; 83(2):283-8. PubMed ID: 24315957
[TBL] [Abstract][Full Text] [Related]
13. Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases.
De Bruyne S; Van Damme N; Smeets P; Ferdinande L; Ceelen W; Mertens J; Van de Wiele C; Troisi R; Libbrecht L; Laurent S; Geboes K; Peeters M
Br J Cancer; 2012 Jun; 106(12):1926-33. PubMed ID: 22596235
[TBL] [Abstract][Full Text] [Related]
14. Short-course radiation followed by mFOLFOX-6 plus avelumab for locally-advanced rectal adenocarcinoma.
Shamseddine A; Zeidan YH; Kreidieh M; Khalifeh I; Turfa R; Kattan J; Mukherji D; Temraz S; Alqasem K; Amarin R; Al Awabdeh T; Deeba S; Jamali F; Mohamad I; Elkhaldi M; Daoud F; Al Masri M; Dabous A; Hushki A; Jaber O; Khoury C; El Husseini Z; Charafeddine M; Al Darazi M; Geara F
BMC Cancer; 2020 Sep; 20(1):831. PubMed ID: 32873251
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant oxaliplatin and capecitabine and bevacizumab without radiotherapy for poor-risk rectal cancer: N-SOG 03 Phase II trial.
Uehara K; Hiramatsu K; Maeda A; Sakamoto E; Inoue M; Kobayashi S; Tojima Y; Yoshioka Y; Nakayama G; Yatsuya H; Ohmiya N; Goto H; Nagino M
Jpn J Clin Oncol; 2013 Oct; 43(10):964-71. PubMed ID: 23935207
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the changes induced by bevacizumab using a high temporal resolution DCE-MRI as prognostic factors for response to further neoadjuvant chemotherapy.
Etxano J; Insausti LP; Elizalde A; López Vega JM; Plazaola A; Martínez P
Acta Radiol; 2015 Nov; 56(11):1300-7. PubMed ID: 25348477
[TBL] [Abstract][Full Text] [Related]
17. Predicting nodal status using dynamic contrast-enhanced magnetic resonance imaging in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy with and without sequential trastuzumab.
Hsiang DJ; Yamamoto M; Mehta RS; Su MY; Baick CH; Lane KT; Butler JA
Arch Surg; 2007 Sep; 142(9):855-61; discussion 860-1. PubMed ID: 17875840
[TBL] [Abstract][Full Text] [Related]
18. [Predictive value of quantitative dynamic contrast-enhanced magnetic resonance imaging for the efficacy of neoadjuvant chemotherapy in locally advanced gastric cancer].
Zhu YJ; Li Y; Jiang J; Zhang W; Xue LY; Zhou AP; Jiang LM
Zhonghua Zhong Liu Za Zhi; 2019 Oct; 41(10):765-770. PubMed ID: 31648499
[No Abstract] [Full Text] [Related]
19. DCE-MRI time-intensity curve visual inspection to assess pathological response after neoadjuvant therapy in locally advanced rectal cancer.
Petrillo A; Fusco R; Petrillo M; Granata V; Bianco F; Di Marzo M; Delrio P; Tatangelo F; Botti G; Pecori B; Avallone A
Jpn J Radiol; 2018 Oct; 36(10):611-621. PubMed ID: 30039258
[TBL] [Abstract][Full Text] [Related]
20. Association between serial dynamic contrast-enhanced MRI and dynamic 18F-FDG PET measures in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer.
Partridge SC; Vanantwerp RK; Doot RK; Chai X; Kurland BF; Eby PR; Specht JM; Dunnwald LK; Schubert EK; Lehman CD; Mankoff DA
J Magn Reson Imaging; 2010 Nov; 32(5):1124-31. PubMed ID: 21031518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]